Cargando…
CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
Metastatic progression and tumor evolution complicates the clinical management of cancer patients. Circulating tumor cell (CTC) characterization is a growing discipline that aims to elucidate tumor metastasis and evolution processes. CTCs offer the clinical potential to monitor cancer patients for t...
Autores principales: | Ffrench, B., Kashdan, E., Huang, Y., Spillane, C.D., Cocchiglia, S., Charmsaz, S., Varešlija, D., O'Brien, C., Scholz, D., Martin, C., Gallagher, M., Brooks, D.A., Brooks, R.D., Selemidis, S., Gleeson, N., AbuSaadeh, F., O'Riain, C., Kamran, W., Flavin, R., Young, L., O'Toole, S.A., O'Leary, J.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898658/ https://www.ncbi.nlm.nih.gov/pubmed/36747925 http://dx.doi.org/10.1016/j.heliyon.2023.e13044 |
Ejemplares similares
-
Ex vivo expansion of circulating tumour cells (CTCs)
por: Mohamed, Bashir M., et al.
Publicado: (2023) -
The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer
por: Bates, Mark, et al.
Publicado: (2020) -
CD10(−)/ALDH(−) cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy
por: Ffrench, Brendan, et al.
Publicado: (2017) -
Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples
por: Gallagher, Michael F, et al.
Publicado: (2012) -
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)